CBD Research Points to Brain-System Effects Relevant to Alcohol Use Disorder
A 2024 systematic review suggests that cannabidiol (CBD) influences several brain systems involved in alcohol use disorder (AUD), including circuits associated with reward, emotional regulation, salience and executive control. The findings provide a rationale for further research—but they do not establish CBD as an effective treatment for AUD.
Published in the Journal of Cannabis Research, the review examined the neuroimaging evidence on CBD and its potential relevance to alcohol use disorder. Researchers searched 767 studies and included 16 that used techniques such as functional magnetic resonance imaging, positron-emission tomography and magnetic resonance spectroscopy.
The central limitation is that the review focused on studies of CBD’s effects in healthy participants rather than people diagnosed with AUD. The authors therefore used the findings to propose possible mechanisms, not to demonstrate that CBD reduces drinking, prevents relapse or improves recovery outcomes.
Across the studies, CBD appeared to alter activity or connectivity in regions involved in reward anticipation, salience processing, emotion and cognitive control. The review also identified evidence that CBD may affect gamma-aminobutyric acid (GABA) and glutamate signaling in areas including the basal ganglia and dorsomedial prefrontal cortex.
These observations are relevant because long-term, heavy alcohol use is associated with changes in brain networks involved in reward processing, stress, emotion regulation and decision-making. Those changes can contribute to alcohol craving, cue-driven drinking and difficulty controlling consumption. CBD’s effects on some of the same circuits could, in theory, help regulate processes linked to alcohol-seeking behavior.
However, the evidence was not entirely consistent. The studies differed in their doses, timing, imaging methods and participant characteristics, and some may have drawn on overlapping samples. Most measured short-term brain responses rather than meaningful clinical outcomes such as reduced alcohol consumption, sustained abstinence or lower relapse rates.
For that reason, the review’s conclusion was appropriately cautious: CBD may modulate neurobiological systems implicated in AUD, but studies involving people with AUD are needed to determine whether those changes translate into therapeutic benefits. Randomized clinical trials will also need to establish effective doses, longer-term safety and whether CBD works better than—or adds value to—existing treatments.
CBD should not be viewed as a substitute for established care. In the United States, the National Institute on Alcohol Abuse and Alcoholism outlines behavioral treatments and FDA-approved medications for AUD, including naltrexone, acamprosate and disulfiram. Anyone considering CBD should also discuss it with a health professional: the U.S. Food and Drug Administration warns about potential drug interactions, liver injury and other safety concerns.
The review offers a useful map of how CBD might affect addiction-related brain circuitry. It does not yet show that CBD can treat alcohol use disorder, but it identifies testable mechanisms that future clinical research can investigate.
